# Beijing Continent Pharmaceutical Co, Ltd. trials: 26 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with Beijing Continent Pharmaceutical Co, Ltd. as lead sponsor, 7 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Beijing Continent Pharmaceutical Co, Ltd.: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/beijing-continent-pharmaceutical-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 7
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| March 13, 2026 | NCT07471217 | \[¹⁴C\] Hydronidone Mass Balance Study | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Chronic Hepatitis B-related Liver Fibrosis | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07471217) |
| February 18, 2026 | NCT07417553 | A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis | Beijing Continent Pharmaceutical Co, Ltd. | Phase 2 | Completed | Chronic Hepatitis B-related Liver Fibrosis | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07417553) |
| February 17, 2026 | NCT07412236 | A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic... | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Recruiting | Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B | 1,208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412236) |
| February 6, 2026 | NCT07394309 | Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Liver Fibrosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07394309) |
| February 5, 2026 | NCT07388680 | Pirfenidone Capsules in the Treatment of Radiation-induced Lung Injury With or Without Immune Pneumonia | Beijing Continent Pharmaceutical Co, Ltd. | Phase 2/3 | Recruiting | Radiation-induced Lung Injury, Immune-related Pneumonia | 298 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07388680) |
| January 23, 2026 | NCT07364448 | A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis | Beijing Continent Pharmaceutical Co, Ltd. | Phase 2 | Completed | Chronic Hepatitis B With Hepatic Fibrosis | 411 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07364448) |
| January 15, 2026 | NCT07343778 | A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Completed | Chronic Hepatitis B With Hepatic Fibrosis | 337 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07343778) |
| December 22, 2025 | NCT07295873 | Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir... | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction) | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07295873) |
| December 4, 2025 | NCT07263152 | QTc Assessment in a Single-Dose Study of Hydronidone Capsules | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Hepatic Fibrosis | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07263152) |
| December 3, 2025 | NCT07262346 | The Phase Ⅰd Clinical Trial of Hydronidone Capsules | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Liver Fibrosis | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262346) |
| December 3, 2025 | NCT07262333 | A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Recruiting | Renal Insufficiency Chronic | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07262333) |
| March 28, 2025 | NCT06899815 | Preliminary Human Trials of F230 Tablets | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Recruiting | Pulmonary Hypertension | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06899815) |
| June 15, 2023 | NCT05905172 | Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Recruiting | Liver Fibrosis | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905172) |
| January 19, 2023 | NCT05689645 | F573 for Injection for the Treatment of Liver Injury/Failure | Beijing Continent Pharmaceutical Co, Ltd. | Phase 2 | Recruiting | Acute Liver Failure, Acute-On-Chronic Liver Failure | 97 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05689645) |
| March 21, 2022 | NCT05288179 | Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Recruiting | Pneumoconiosis | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05288179) |
| November 10, 2021 | NCT05115942 | Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial. | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Completed | Liver Fibrosis | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05115942) |
| March 29, 2021 | NCT04820049 | F573 Ia Clinical Trial | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Tolerance, Pharmacokinetic | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04820049) |
| November 14, 2019 | NCT04162821 | Study on Pharmacokinetics of Hydronidone | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Pharmacokinetics of Hydronidone | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04162821) |
| October 15, 2019 | NCT04126538 | Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Unknown | Renal Insufficiency | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04126538) |
| October 14, 2019 | NCT04125056 | Study on Hydronidone Capsule BE | Beijing Continent Pharmaceutical Co, Ltd. | Not applicable | Completed | Healthy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04125056) |
| October 11, 2019 | NCT04124081 | Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Hydronidone | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04124081) |
| October 11, 2019 | NCT04123769 | Study on PK of Hydronidone in Patients and Special Population | Beijing Continent Pharmaceutical Co, Ltd. | Phase 1 | Completed | Hepatitis b & Liver Dysfunction | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04123769) |
| April 4, 2019 | NCT03902509 | A Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury. | Beijing Continent Pharmaceutical Co, Ltd. | Phase 2 | Completed | Radiation-induced Lung Injury | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03902509) |
| February 28, 2019 | NCT03857854 | Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Unknown | Dermatomyositis Interstitial Lung Disease (Dm-ILD) | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03857854) |
| February 27, 2019 | NCT03856853 | Efficacy and Safety of Pirfenidone in Patient With Systemic Sclerosis-associated Interstitial Lung Disease | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Unknown | Systemic Sclerosis-associated Interstitial Lung Disease (Ssc-ild) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03856853) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 12 |
| Phase 2 | 5 |
| Phase 2/3 | 1 |
| Phase 3 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 15 |
| Recruiting | 7 |
| Unknown | 4 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Liver Cirrhosis | 6 |
| Renal Insufficiency, Chronic | 1 |
| Renal Insufficiency | 1 |
| Hepatitis B | 1 |
| Liver Diseases | 1 |
| Pneumoconiosis | 1 |
| Hypertension, Pulmonary | 1 |
| Radiation Pneumonitis | 1 |
| Liver Failure, Acute | 1 |
| Acute-On-Chronic Liver Failure | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Business schools in the United States](https://specstream.ai/data/businesses/business-schools/united-states)
- [Billing services in the United States](https://specstream.ai/data/businesses/billing-services/united-states)
- [B2B scientific equipment companies in the United States](https://specstream.ai/data/businesses/b2b-scientific-equipment-companies/united-states)
- [Awning suppliers in the United States](https://specstream.ai/data/businesses/awning-suppliers/united-states)
- [American restaurants in the United States](https://specstream.ai/data/businesses/american-restaurants/united-states)
